Axel Ullrich
89Patents
26h-index
98Co-inventors
91Inventor score
Filing activity: Sep 11, 1981 → Nov 26, 2014
Most-cited inventions
| Patent | Title | Area | Cited by | Status |
|---|---|---|---|---|
| US5677171A | Monoclonal antibodies directed to the HER2 receptor | Chemistry; Metallurgy | 422 | Expired |
| US5770195A | Monoclonal antibodies directed to the her2 receptor | Chemistry; Metallurgy | 253 | Expired |
| US5725856A | Monoclonal antibodies directed to the HER2 receptor | Human Necessities | 243 | Expired |
| US5772997A | Monoclonal antibodies directed to the HER2 receptor | Chemistry; Metallurgy | 229 | Expired |
| US5720954A | Monoclonal antibodies directed to the HER2 receptor | Chemistry; Metallurgy | 171 | Expired |
| US6165464A | Monoclonal antibodies directed to the HER2 receptor | Chemistry; Metallurgy | 171 | Expired |
| US4859609A | Novel receptors for efficient determination of ligands and their antagonists or agonists | Emerging Cross-Sectional Technologies | 160 | Expired |
| US6015567A | HER2 extracellular domain | Human Necessities | 153 | Expired |
| US6399063B1 | Monoclonal antibodies directed to the HER2 receptor | Chemistry; Metallurgy | 153 | Expired |
| US6387371B1 | Monoclonal antibodies directed to the HER2 receptor | Chemistry; Metallurgy | 137 | Expired |
| US6326469A | Megakaryocytic protein tyrosine kinases | Chemistry; Metallurgy | 121 | Expired |
| US5720937A | In vivo tumor detection assay | Human Necessities | 112 | Expired |
| US4761371A | Insulin receptor | Human Necessities | 110 | Expired |
| US5851999A | FLK-1 is a receptor for vascular endothelial growth factor | Physics | 88 | Expired |
| US6331555A | Treatment of platelet derived growth factor related disorders such as cancers | Human Necessities | 81 | Expired |
| US6333169A | HER2 extracellular domain | Human Necessities | 79 | Expired |
| US5700823A | Treatment of platelet derived growth factor related disorders such as cancers | Emerging Cross-Sectional Technologies | 76 | Expired |
| US5030576A | Receptors for efficient determination of ligands and their antagonists or agonists | Physics | 69 | Expired |
| US6177401A | Use of organic compounds for the inhibition of Flk-1 mediated vasculogenesis and angiogenesis | Physics | 60 | Expired |
| US4933294A | Method of detecting truncated epidermal growth factor receptors | Emerging Cross-Sectional Technologies | 56 | Expired |
| US5990141A | Treatment of platelet derived growth factor related disorders such as cancers | Emerging Cross-Sectional Technologies | 47 | Expired |
| US4440859A | Method for producing recombinant bacterial plasmids containing the coding sequences of higher organisms | Chemistry; Metallurgy | 45 | Expired |
| US5700822A | Treatment of platelet derived growth factor related disorders such as cancers | Emerging Cross-Sectional Technologies | 32 | Expired |
| US4652525A | Recombinant bacterial plasmids containing the coding sequences of insulin genes | Emerging Cross-Sectional Technologies | 32 | Expired |
| US7531304B2 | Method for screening FGFR-4 agonists | Physics | 27 | Expired |
Source: USPTO / EPO open patent data. Inventor disambiguation is heuristic; counts are objective bibliographic measures.